Silphium Asset Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Silphium Asset Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,341	Closed	-$167K	–	160
2018 Q2	$167K	Buy	+2,341	New	+$165K	0.05%	101
2018 Q1	–	Sell	-558	Closed	-$70.3K	–	98
2017 Q4	$70.3K	Buy	+558	New	+$71.5K	0.09%	56

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Silphium Asset Management's TTPH Position: Q3 2018 in Review

Silphium Asset Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2018, closing a stake of 2,341 shares — an estimated $167K sold.

Silphium Asset Management first reported a position in TTPH in Q4 2017 and held it in 2 quarters. The position peaked at $167K in Q2 2018. 92 funds tracked by Wall St. Rank hold TTPH as of Q3 2018.

Silphium Asset Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Silphium Asset Management sold 2,341 Tetraphase Pharmaceuticals, Inc. shares in Q3 2018, an estimated $167K.
Silphium Asset Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2017 and held it in 2 quarters.
Silphium Asset Management's Tetraphase Pharmaceuticals, Inc. position peaked at $167K in Q2 2018.
92 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2018.

Based on Silphium Asset Management's 13F filing for Q3 2018, filed 30 Jan 2025.